This is a moderately important lift for SNTA which has the most advanced HSP90 inhibitor ganetespib. Everyone is clamoring for use of this drug in crizotinib failure patients, either alone or in combo with retreatment for ALK population in NSCLC. This has been discussed repeatedly on calls/webcasts since ASCO 2011.
Having criz approved simplifies the trial planning, and I think something will be underway within months, as soon as either 1) some coop group ays for it, 2) SNTA inks an asian partnership with large upfront cash, or (if they just cut to the chase) 3) PFE buys SNTA
Market Data 
Markets 
AI
